Insmed drug failure in a study leads to a valuation drop of nearly 20%, affecting its $40 billion market cap.
Author: PharmaSignal News Desk
why-approved-filings-unravel-after-central-teams-disengage
The deal made sense on paper At signing, the global deal thesis was tight. Clear rNPV logic, credible peak sales, realistic launch sequencing, and a partner narrative that aligned with portfolio strategy. Central BD and global commercial teams could defend every assumption. Management bought the story. Then the asset moved from global governance to affiliate execution. That is where most deal theses quietly die. Not because the asset failed clinically. Not because the contract was flawed. But because the value assumptions embedded in the deal were never translated into operating KPIs that affiliates could actually run. Handover is treated as…
Orum $100M financing supports its strategic shift towards developing a blood cancer treatment, enhancing its innovative pipeline.
GSK asthma drug approval marks a significant milestone with FDA clearance of Exdensur for twice-yearly dosing, impacting severe asthma care.
Peanut allergy patch shows positive results in Phase 3 study, paving way for 2026 FDA submission.
RA Capital co-leads a $125 million Series A for Ambros Therapeutics, advancing a chronic pain drug nearing pivotal testing.
Addition Therapeutics secures $100M to advance RNA-lipid nanoparticle gene therapies, backed by Gates Foundation.
Nektar autoimmune drug shows promise in alopecia study, despite missing statistical success, supporting late-stage testing.
FDA fast pass J&J for multiple myeloma regimen, impacting treatment timelines.